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Abstract The p42/44 mitogen-activated protein (MAP)-kinase
cascade is a well-established signal transduction pathway that is
initiated at the cell surface and terminates within the nucleus.
More specifically, receptor tyrosine kinases can indirectly
activate Raf, which in turn leads to activation of MEK and
ERK and ultimately phosphorylation of Elk, a nuclear transcrip-
tion factor. Recent reports have suggested that some members of
p42/44 MAP kinase cascade can be sequestered within
plasmalemmal caveolae in vivo. For example, morphological
studies have directly shown that ERK-1/2 is concentrated in
plasma membrane caveolae in vivo using immunoelectron
microscopy. In addition, constitutive activation of the p42/44
MAP kinase cascade is sufficient to reversibly down-regulate
caveolin-1 mRNA and protein expression. However, the func-
tional relationship between the p42/44 MAP kinase cascade and
caveolins remains unknown. Here, we examine the in vivo role of
caveolins in regulating signaling along the MAP kinase cascade.
We find that co-expression with caveolin 1 dramatically inhibits
signaling from EGF-R, Raf, MEK-1 and ERK-2 to the nucleus.
Using a variety of caveolin-1 deletion mutants, we mapped this in
vivo inhibitory activity to caveolin-1 residues 32^95. Peptides
derived from this region of caveolin 1 also inhibit the in vitro
kinase activity of purified MEK-1 and ERK-2. Thus, we show
here that caveolin-1 expression can inhibit signal transduction
from the p42/44 MAP kinase cascade both in vitro and in vivo.
Taken together with previous data, our results also suggest that a
novel form of reciprocal negative regulation exists between p42/
44 MAP kinase activation and caveolin-1 protein expression, i.e.
up-regulation of caveolin-1 protein expression down-modulates
p42/44 MAP kinase activity (this report) and up-regulation of
p42/44 MAP kinase activity down-regulates caveolin-1 mRNA
and protein expression.
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1. Introduction
Caveolae are 50^100-nm vesicular invaginations of the plas-
ma membrane [1,2]. They represent a sub-compartment of the
plasma membrane. It has been proposed that caveolae partic-
ipate in vesicular tra⁄cking events and signal transduction
processes. Caveolae are most abundant in terminally di¡er-
entiated cells, such as adipocytes, endothelial cells and muscle
cells [3^10]. Conversely, caveolae are down-regulated in re-
sponse to activated oncogenes, such as v-Abl and H-Ras
[11,12].
Caveolin, a 21^24-kDa integral membrane protein, is a
principal component of caveolae membranes in vivo. [13^
17]. Caveolin is only the ¢rst member of a new gene family;
as a consequence, caveolin has been re-termed caveolin 1 [5].
Caveolin 2 shows the same tissue distribution as caveolin 1,
co-localizes with caveolin 1 and forms a hetero-oligomeric
complex with caveolin 1 in vivo [18]. In contrast, caveolin 3
is a muscle speci¢c caveolin-related protein that is only ex-
pressed in striated muscle cell types (cardiac and skeletal) [19^
21].
It has been proposed that caveolin family members function
as sca¡olding proteins [22] to organize and concentrate spe-
ci¢c lipids (cholesterol and glycosphingolipids; [23^25]) and
lipid-modi¢ed signaling molecules (Src-like kinases, H-Ras,
eNOS and G-proteins; [23,26^30]) within caveolae mem-
branes. These and other signaling molecules appear to be
tightly associated as a discrete complex with caveolin 1 as
shown using a poly-histidine tagged form of caveolin for de-
tergent-free a⁄nity puri¢cation of caveolae membranes [27].
Based on these and other observations, we and others have
proposed the ‘caveolae signaling hypothesis’, which states that
caveolar localization of certain inactive signaling molecules
could provide a compartmental basis for their regulated acti-
vation and explain cross-talk between di¡erent signaling path-
ways [31^36]. In support of this idea, caveolin-1 binding can
functionally suppress the GTPase activity of hetero-trimeric
G-proteins and inhibit the kinase activity of Src-family tyro-
sine kinases, the EGF-receptor kinase, and protein kinase C
through a common caveolin domain, termed the caveolin-
sca¡olding domain [26^28,37^39]. Thus, we have suggested
that caveolin may function as a negative regulator of many
di¡erent classes of signaling molecules through the recogni-
tion of speci¢c caveolin-binding motifs [37,40].
Recently, caveolae have also been implicated in signaling
through the p42/44 MAP kinase pathway. Evidence has
been presented suggesting that receptor tyrosine kinases
(EGF-R; PDGF-R; Ins-R) [41^45], as well as other compo-
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nents of the p42/44 MAP kinase cascade are localized within
caveolae membranes. These include H-Ras [27,42], Raf kinase
[42], 14-3-3 proteins [43], ERK [33,43], Shc [43], Grb-2 [43],
mSos-1 [43], and Nck [43]. In addition, morphological studies
have directly shown that ERK-1/2 is concentrated in plasma
membrane caveolae in vivo using immunoelectron microscopy
[44]. The functional signi¢cance of the caveolar localization of
the p42/44 MAP kinase cascade remains unknown.
Here, we present evidence that caveolin can regulate signal-
ing via the p42/44 MAP kinase cascade. We show that co-
expression with caveolin 1 dramatically inhibits signaling from
EGF-R, Raf, MEK-1 and ERK-2 to the nucleus in vivo. In
addition, we localize this caveolin-dependent inhibitory activ-
ity to caveolin-1 residues 32^95 using an in vivo assay and
show that peptides from this region of caveolin 1 directly
inhibit the kinase activities of puri¢ed MEK-1 and ERK-2
in vitro. Taken together with previous data, our results also
suggest that a novel form of reciprocal negative regulation
exists between p42/44 MAP kinase activation and caveolin-1
protein expression, i.e. up-regulation of caveolin-1 protein ex-
pression down-modulates p42/44 MAP kinase activity (this
report) and up-regulation of p42/44 MAP kinase activity
down-regulates caveolin-1 mRNA and protein expression [12].
2. Materials and methods
2.1. Materials
The cDNAs encoding caveolins 1, 2, and 3, as well as a panel of
caveolin-1 deletion mutants, were as we described previously [5,20,31].
Antibodies and their sources were as follows: anti-EGFR (mAb 13;
Transduction Laboratories); anti-myc (mAb 9E10; Santa Cruz Bio-
tech). A variety of other reagents were purchased commercially: fetal
bovine serum (FBS; JRH Biosciences); pre-stained protein markers
(Gibco-BRL). The PathDetect Elk-1 in vivo trans-reporting system
was purchased from Stratagene. CHO cells (GRC LR-73) were the
generous gift of Dr. Je¡rey Pollard and were as described previously
[46]. Constructs encoding EGF-R (wt); EGF-R (kd, K721M); Raf-1
(ca, BXB); Raf-1 (kd, K375W); HA-ERK-2; and MEK-1 (ca, S218/
222E-v32-51), were as previously described [47^49]. MEK (PD 98059)
and p38 MAP kinase (SB203580) inhibitors were purchased from
Calbiochem., Inc.
2.2. Cell culture
CHO cells were propagated in t75 tissue-culture £asks in DME
supplemented with antibiotics and 10% serum, as described previously
[46].
2.3. Assay for in vivo signal transduction
To measure in vivo signal transduction, we employed the PathDe-
tect Elk trans-Reporting System (Stratagene, Inc). This assay employs
a fusion protein that contains the DNA binding domain of GAL4 and
the transactivation domain of Elk to induce expression of a luciferase
reporter driven by an arti¢cial promoter containing ¢ve GAL4 bind-
ing sites. When MAPK (p42/44 ERK-1/2) is speci¢cally activated, it
phosphorylates the transactivation domain of Elk which in turn acti-
vates transcription of the luciferase gene from the reporter plasmid.
Experiments testing a plasmid encoding only the GAL4 DNA binding
domain demonstrated that luciferase expression is speci¢cally depend-
ent on activation of the Elk transactivation domain (data not shown).
Transient transfections were performed using calcium phosphate pre-
cipitation. Brie£y, 300 000 CHO cells were seeded in 6-well plates 12^
24 h before the transfection. Each point was transfected with 1 Wg of a
plasmid encoding a form of either EGF-R, Raf-1, ERK-2 or MEK-2,
1 Wg of pFR-Luc, 50 ng of pFA-Elk (as described by the manufac-
turer, Stratagene, Inc.) and 1 Wg of the indicated caveolin or empty
vector. Twelve hours post-transfection, the cells were rinsed twice with
PBS and incubated in 1% FBS for another 24^36 h. The cells were
then lysed in 200 Wl of extraction bu¡er, 50 Wl of which was used to
measure luciferase activity, as described [50]. Each experimental value
represented graphically is the average of two separate transfections
performed in parallel; error bars represent the observed standard
deviation. All experiments were performed at least three times inde-
pendently and yielded virtually identical results. These assays were
made possible through the use of a special CHO-derived cell line,
called GRC LR-73. Unlike parental CHO cells, GRC LR-73 cells
are a non-transformed growth control revertant that has normal ¢-
broblastic morphology, does not grow in suspension, requires high
serum concentrations for growth and undergoes synchronized growth
arrest in low concentrations of serum (1^2%) without a loss of via-
bility [46]. Also, these cells have a much higher transfection e⁄ciency
(V10-fold) than parental CHO cells.
2.4. Immunoblotting
Samples were separated by SDS-PAGE and transferred to nitro-
cellulose. After transfer, nitrocellulose sheets were stained with Pon-
ceau S to visualize protein bands and subjected to immunoblotting.
For immunoblotting, incubation conditions were as described by the
manufacturer (Amersham), except that we supplemented our blocking
solution with both 1% BSA and 2% non-fat dry milk (Carnation).
2.5. Puri¢cation of recombinant MEK-1, ERK-2 and Elk-1
The cDNA clones for rabbit MEK1 and constitutively active
MEK1 (MEKmu, S217E/S221E; [51]) were ligated into pGEX-3X
[52] and expressed in E. coli strain BL-21 as described by Catling et
al. [53]. Cells were suspended in bu¡er (20 mM PIPES, 100 mM NaCl,
0.1% Triton X-100, 5% glycerol, 10 Wg/ml aprotinin, 10 Wg/ml baci-
tracin, 1 mM benzamidine, and 20 Wg/ml leupeptin), sonicated, and
lysates were clari¢ed by centrifugation. Recombinant MEK1 was iso-
lated by glutathione a⁄nity chromatography in 20 mM PIPES, 100
mM NaCl. Mouse ERK2 and inactive ERK2 (ERKmu, K52R; [54])
were ligated into pMal-CR1 (New England Biolabs) and expressed in
E. coli strain TB-1. Cells were sonicated in sonication bu¡er, and
recombinant ERK2 was isolated by amylose resin chromatography
in 20 mM PIPES, 100 mM NaCl. Active recombinant ERK2 was
prepared by incubating recombinant ERK2 bound to amylose resin
with puri¢ed recombinant MEKmu in kinase bu¡er (20 mM PIPES,
100 mM NaCl, 20 mM MgCl2, and 1 mM ATP). Amylose-bound
activated ERK2 was washed with high salt bu¡er (20 mM PIPES,
500 mM NaCl) to remove MEKmu, and eluted with 5 mM maltose.
Residues 307^428 of Elk-1 were expressed as a fusion protein from
pGEX-30X [55] and isolated by glutathione a⁄nity chromatography
in 20 mM PIPES, 100 mM NaCl. Note that GST-MEK-1 constructs
were obtained from Dr. C. Marshall (Chester Beatty Laboratories,
Institute of Cancer Research, University of London) through Dr. R.
Krauss (Mount Sinai School of Medicine); MBP-ERK2 constructs
were donated by Dr. M. Weber (University of Virginia); and the
GST-ElkC construct was provided by Dr. R. Treisman (Transcription
Laboratory, Imperial Cancer Research Fund).
2.6. In vitro kinase assays
Kinase reactions were performed in 20 mM PIPES, 100 mM NaCl,
50 WM ATP, 20 mM MgCl2, and 1 WCi [Q-32P]-ATP. Reactions typ-
ically contained 0.5 Wg of enzyme and 1 Wg of substrate in a ¢nal
volume of 20 Wl. Kinase reactions were allowed to proceed for 5 min
at room temperature, and stopped by the addition of EDTA to 50
mM ¢nal concentration. Samples were resolved by SDS-PAGE and
detected by autoradiography. Quantitation was performed by phos-
phor-imager analysis.
3. Results
3.1. Recombinant expression of caveolin 1 suppresses EGF-R
mediated signal transduction in vivo
EGF-R is thought to signal through the activation of the
p42/44 MAP kinase cascade. It is well known that transient
over-expression of EGF-R is su⁄cient to cause receptor di-
merization and signal transduction. Thus, we employed a
MAP kinase reporter system (from Stratagene, Inc.) to meas-
ure EGF-R mediated signal transduction in vivo. This assay
employs a fusion protein that contains the DNA binding
domain of GAL4 and the transactivation domain of Elk to
induce expression of a luciferase reporter driven by an arti¢-
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cial promoter containing ¢ve GAL4 binding sites. When
MAPK (p42/44 ERK-1/2) is speci¢cally activated, it phos-
phorylates the transactivation domain of Elk which in turn
activates transcription of the luciferase gene from the reporter
plasmid. Experiments using a plasmid encoding only the
GAL4 DNA binding domain demonstrated that luciferase
expression is speci¢cally dependent on activation of the Elk
transactivation domain (data not shown).
These assays were made possible through the use of a spe-
cial CHO-derived cell line, called GRC LR-73. Unlike pa-
rental CHO cells, GRC LR-73 cells are a non-transformed
growth control revertant that has normal ¢broblastic mor-
phology, does not grow in suspension, requires high serum
concentrations for growth and undergoes synchronized
growth arrest in low concentrations of serum (1^2%) without
a loss of viability [46]. Also, these cells have a much higher
transfection e⁄ciency (V10-fold) than parental CHO cells.
Transactivation of Elk can occur via phosphorylation by
either the p42/44 MAP kinase (ERK) or via phosphorylation
by p38 MAP kinases. To establish which MAP kinase path-
way is activated by EGF-R over-expression, we used two well-
characterized inhibitors. PD 98059 is a speci¢c inhibitor of
MEK-1/2 that is just upstream of ERK and SB 203580 is a
speci¢c inhibitor of p38 MAP kinases. Fig. 1 shows that treat-
ment with PD 98059 inhibited EGF-R mediated signaling to
Elk by V65^70%, while SB 203580 had little or no e¡ect.
These results indicate that EGF-R mediated transcriptional
activation of Elk occurs primarily through the classical p42/
44 MAP kinase cascade.
We next used this assay system to test the hypothesis that
caveolin-1 expression inhibits EGF-R mediated signaling in
vivo. Although these cells endogenously express low levels
of both caveolins 1 and 2, much higher levels of caveolin
expression were achieved by transient expression of recombi-
nant caveolins using constitutive expression driven by CMV-
based vectors. As shown in Fig. 2A, co-expression with cav-
eolin 1 dramatically inhibited EGF-R-mediated signal trans-
duction by approximately 20-fold. In contrast, co-transfection
with L-galactosidase or with the empty vector used to express
caveolin 1 (pCB7) had no e¡ect on EGF-R mediated signal-
ing. As expected, a kinase dead (kd) form of EGF-R did not
show any signaling capacity in this assay system.
To rule out the possibility that co-expression with caveolin
1 would block or reduce expression of EGF-R, cell lysates
were prepared after co-transfection and the levels of EGF-R
expression were assessed by immunoblot analysis. Fig. 2B
shows that EGF-R expression is una¡ected by co-transfection
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Fig. 1. Overexpression of EGF-R activates the p42/44 MAP kinase
cascade, but not the p38 MAP kinase cascade. Transient co-expres-
sion of EGF-R with a luciferase reporter plasmid allows us to meas-
ure the transactivation of the transcription factor Elk. Transactiva-
tion of Elk can occur via phosphorylation by either the p42/44
MAP kinase (ERK) or via phosphorylation by p38 MAP kinases.
To establish which MAP kinase pathway is activated by EGF-R
overexpression, we used two well-characterized inhibitors: PD 98059
(100 WM) and SB 203580 (20 WM). Note that treatment with PD
98059 inhibited EGF-R mediated signaling to Elk by V65-70%,
while SB 203580 had little or no e¡ect. These results indicate that
EGF-R mediated transcriptional activation of Elk occurs primarily
through the classical p42/44 MAP kinase cascade. RLU, relative
light units. Each experimental value represented graphically is the
average of two separate transfections performed in parallel ; error
bars represent the observed standard deviation. These experiments
were performed at least three times independently and yielded virtu-
ally identical results.
Fig. 2. Caveolin-1 expression blocks EGF-R mediated signal trans-
duction to the nucleus in vivo. A: Transient co-expression of EGF-
R with a luciferase reporter plasmid allowed us to measure the
transactivation of the transcription factor Elk that is a substrate for
MAP kinases (see Section 2). Note that co-expression with caveolin
1 dramatically inhibited EGF-R-mediated signal transduction
evoked by overexpression of wild-type (wt) EGF-R by approxi-
mately V10^20-fold. Importantly, co-transfection with the empty
vector used to express caveolin 1 (pCB7) or with L-galactosidase
had no e¡ect on EGF-R mediated signaling. The activity of kinase
dead (kd) EGF-R was evaluated in parallel as a negative control.
Each experimental value represented graphically is the average of
two separate transfections performed in parallel; error bars repre-
sent the observed standard deviation. These experiments were per-
formed at least three times independently and yielded virtually iden-
tical results. B: Co-expression with caveolin 1 does not a¡ect the
expression levels of transfected EGF-R. CHO cells were transiently
transfected with EGF-R plus caveolin 1, EGF-R plus empty vector
(pCB7), or mock-transfected. Lysates were prepared and subjected
to immunoblot analysis with an anti-EGF-R speci¢c mAb probe.
Note that EGF-R expression is una¡ected by co-transfection with
caveolin 1.
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with caveolin 1, as compared to co-transfection with the
empty pCB7 vector. This result also underscores that the
transfection e⁄ciencies were quite comparable. In addition,
all luciferase assay experiments were repeated several times
independently and invariably yielded similar results.
3.2. Deletion mutagenesis de¢nes a region of caveolin 1 that
inhibits EGF-R-mediated signal transduction
We next employed this assay system and a variety of cav-
eolin-1 deletion mutants to map this caveolin-1 dependent
inhibitory activity to a given region of the caveolin-1 mole-
cule. The caveolin-1 deletion mutants that were used are
shown schematically in Fig. 3A. Note that the full-length cav-
eolin-1 molecule contains residues 1^178 (K-isoform), the L-
isoform lacks residues 1^31, vC lacks residues 141^178 of the
C-terminal domain, and vN lacks residues 1^95 of the N-
terminal domain. These constructs have all been previously
characterized and are expressed to equivalent levels in trans-
fected cells [56].
Fig. 3B shows the results of a typical experiment analyzing
these di¡erent caveolin mutants. The graph is depicted on a
log scale so one can best appreciate the true di¡erences in
inhibitory activity displayed by these mutants. Values are rep-
resented as inhibition relative to Caveolin-1 FL. Relative to
wild-type full-length caveolin 1 (FL; K-isoform), vC was
V10^20-fold more potent, and vN wasV10-fold less potent;
the L-isoform was almost as potent as wild-type full-length
caveolin 1. In addition, full-length caveolins 1, 2, and 3 all
showed similar inhibitory activities. From this mutational
analysis, we can conclude that the in vivo inhibitory activity
of caveolin 1 is contained within the N-terminal domain, and
to a ¢rst approximation, within caveolin-1 residues 32^95.
3.3. Recombinant expression of caveolin 1 suppresses activation
of the MAP kinase cascade in vivo
We next tested the e¡ects of caveolin co-expression on the
in vivo activities of Raf, MEK and ERK kinases. Figs. 4 and
5 show the results of these experiments. In the case of Raf, co-
expression with caveolin 1 dramatically inhibited signaling
mediated by a constitutively active (ca) form of Raf-1 kinase
by V75%. In contrast, co-expression with L-galactosidase had
no e¡ect. In addition, a kinase dead (kd; K375W) form of
Raf-1 did not show any signaling in this assay system as
expected (Fig. 4A).
Similar results were obtained for MEK and ERK. Caveo-
lin-1 co-expression inhibited signaling mediated by a constitu-
tively active form of MEK-1 (v32-51, S 218/222 E) by V20-
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Fig. 3. De¢ning a region of caveolin 1 that blocks EGF-R mediated
signal transduction in vivo. A: Diagram summarizing wild-type cav-
eolin 1 and a series of caveolin-1 deletion mutants. Note that the
full-length caveolin-1 molecule contains residues 1^178 (K-isoform),
the L-isoform lacks residues 1^31, vC lacks residues 141^178 of the
C-terminal domain, and vN lacks residues 1^95 of the N-terminal
domain. B: E¡ects of transiently expressing caveolin-1 deletion mu-
tants and caveolins 2 and 3 on EGF-R-mediated signal transduc-
tion. Di¡erences in inhibitory activity were best visualized by repre-
senting the data on a log scale. The actual average relative light
units (RLU) obtained in this experiment were: 3 658 423 ^ EGFR+-
vector alone (not displayed); 273 506 ^ EGFR+caveolin 1 FL;
18 503 ^ EGFR+caveolin 1 vC; 2 506 019 ^ EFGR+caveolin 1 vN;
558 207 ^ EFGR+caveolin-1 L-isoform; 487 431 ^ EGFR+caveolin
2; 287 238 ^ EGFR+caveolin 3. Each experimental value repre-
sented graphically is the average of two separate transfections per-
formed in parallel; error bars represent the observed standard devia-
tion. These experiments were performed at least three times
independently and yielded virtually identical results.
Fig. 4. Overexpression of caveolin 1 blocks Raf-mediated signal
transduction in vivo. A: E¡ects of full-length caveolin 1 on Raf-
mediated signaling. Note that co-expression with empty vector
(pCB7) or L-galactosidase has no e¡ect on signaling from constitu-
tively active (ca) Raf. The activity of kinase dead (kd) Raf was eval-
uated in parallel as a negative control. B: E¡ects of caveolin-1 dele-
tion mutants, caveolin 2, and caveolin 3 on Raf-mediated signaling.
Transactivation of Elk was measured as luciferase activity as de-
scribed in the legend of Fig. 1. These experiments were performed
at least three times independently and yielded virtually identical re-
sults.
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fold, while caveolin-1 co-expression inhibited signaling medi-
ated by ERK-2 by V10-fold in the same assay system (Fig.
5A,B).
The in vivo e¡ects of caveolin-1 deletion mutants, caveolin
2 and caveolin 3 on the activities of Raf, MEK and ERK were
next evaluated (Figs. 4B and 5C,D). Relative to wild-type full-
length caveolin 1 (FL; K-isoform), vC wasV10^30-fold more
potent, and vN was V4^10-fold less potent; the L-isoform
was almost as potent as wild-type full-length caveolin 1. Also,
full-length caveolins 1, 2, and 3 all showed similar inhibitory
activities toward Raf-1, MEK-1 and ERK-2.
This mutational analysis implicates caveolin-1 residues 32^
95 in the inhibition of in vivo signaling by Raf-1, MEK-1 and
ERK-2. Interestingly, the caveolin-1 sca¡olding domain (res-
idues 82^101) lies within this inhibitory region de¢ned by in
vivo mutational analysis, suggesting that this in vivo inhibi-
tory activity may be due to direct interactions of MEK and
ERK with the caveolin-1 sca¡olding domain.
3.4. Caveolin-derived peptides directly inhibit the kinase
activity of MEK-1 and ERK-2 in vitro
As our above data suggested that caveolin 1 may interact
directly with MEK-1 or ERK-2 in vivo, we decided to test this
hypothesis by reconstituting individual steps within the MAP-
kinase cascade in vitro using puri¢ed recombinant compo-
nents (MEK-1, ERK-2 and Elk) and synthetic peptides (de-
rived from caveolins 1, 2, and 3).
First, the potential inhibitory activities of caveolin-1 derived
peptides were evaluated using an assay that measures the kin-
ase activity of puri¢ed recombinant MEK-1. In this assay
system, puri¢ed recombinant kinase dead ERK-2 (K52R)
was used as the phospho-acceptor substrate for MEK-1
(Fig. 6A). Only the caveolin-1 peptide encoding caveolin-1
residues 82^101 showed signi¢cant inhibitory activity, while
a peptide encoding an adjacent region of caveolin 1 (residues
53^81) had no e¡ect at the same concentration. If the peptide
encoding caveolin-1 residues 82^101 was divided into two
shorter peptides (residues 84^92 and 93^101), its inhibitory
activity was abolished.
As residues 82^101 correspond to the sca¡olding domain in
caveolin 1, we assessed the e¡ects of analogous peptides en-
coding the sca¡olding domains of caveolins 2 and 3. Note
that only the sca¡olding domain of caveolins 1 and 3 showed
inhibitory activity; the sca¡olding domain of caveolin 2 had
no e¡ect. This is consistent with previous reports demonstrat-
ing that only peptides encoding the sca¡olding domains of
caveolins 1 and 3 possess inhibitory activity toward G-pro-
teins, Src-like kinases, eNOS, PKC and EGF-R; the peptide
encoding caveolin 2 has been shown not to be an inhibitor of
these signaling molecules [28,37^39,57].
Next, the potential inhibitory activities of caveolin-1 de-
rived peptides were evaluated using an assay that measures
the kinase activity of puri¢ed recombinant ERK-2 (Fig. 6B).
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Fig. 5. Overexpression of caveolin 1 blocks MEK and ERK-medi-
ated signal transduction in vivo. A: E¡ects of full-length caveolin 1
on MEK1-mediated signaling. B: E¡ects of full-length caveolin 1 on
ERK2-mediated signaling. C: E¡ects of caveolin-1 deletion mutants,
caveolin 2, and caveolin 3 on MEK1-mediated signaling. D: E¡ects
of caveolin-1 deletion mutants, caveolin 2, and caveolin 3 on
ERK2-mediated signaling. Transactivation of Elk was measured as
luciferase activity as described in the legend of Fig. 1. These experi-
ments were performed at least three times independently and yielded
virtually identical results.
Fig. 6. Caveolin-derived peptides directly inhibit the kinase activity
of MEK-1 and ERK-2 in vitro. A: The activity of puri¢ed MEK-1
was assessed using puri¢ed kinase dead ERK-2 (K52R) as the sub-
strate. B: The activity of puri¢ed ERK-2 was assessed using puri¢ed
Elk C-terminus as the substrate. Note that only peptides corre-
sponding to the sca¡olding domains of caveolin 1 (residues 82^101)
and caveolin 3 demonstrated inhibitory activity towards MEK-1
and ERK-2 in vitro. Other caveolin-derived peptides employed
showed no inhibitory activity. SD, sca¡olding domain. All peptides
were added to a ¢nal concentration of 10 WM. These experiments
were performed at least three times independently and yielded virtu-
ally identical results.
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In this assay system, puri¢ed recombinant Elk-C-terminal do-
main was used as the phospho-acceptor substrate for ERK-2.
Using this in vitro assay, virtually identical results were ob-
tained for ERK-2 as with MEK-1.
In these in vitro kinase assays, the caveolin-1 sca¡olding
domain inhibited MEK-1 and ERK-2 with similar potencies
in the micromolar range (IC50 (MEK-1) V1 WM; IC50 (ERK-
2) V2.5 WM) (data not shown). These results suggest that the
sca¡olding domain of caveolin 1 recognizes MEK and ERK
in a similar manner. These values correspond well to those
observed previously for inhibition of other kinases involved in
signal transduction [28,38,39].
4. Discussion
Many distinct classes of signaling molecules are required to
interact sequentially to activate the p42/44 MAP kinase cas-
cade. These include the peptide ligand, the corresponding re-
ceptor tyrosine kinase, adaptor molecules (Grb2, SHC, and
14-3-3), Raf-1, MEK-1/2 and ERK-1/2. Several independent
laboratories have now shown that these components are con-
centrated within caveolae membranes, using both in vitro bio-
chemical methods and in vivo immunolabeling techniques
[27,41^45]. For example, morphological studies have directly
shown that ERK-1/2 is concentrated in plasma membrane
caveolae in vivo using immunoelectron microscopy [44]. How-
ever, the functional signi¢cance of the caveolar localization of
the p42/44 MAP kinase cascade remains unknown.
Here, we have examined if a functional relationship exists
between caveolins and components of the p42/44 MAP kinase
cascade in vivo. Co-expression with caveolin 1 dramatically
inhibited signaling from EGF-R, Raf, MEK-1 and ERK-2 to
the nucleus, as measured using an assay that re£ects the tran-
scriptional activation of Elk, a direct substrate of ERK-1/2.
Using this in vivo assay and a panel of caveolin-1 deletion
mutants, we mapped this caveolin-1-mediated inhibitory ac-
tivity to the N-terminal domain of caveolin, within residues
32^95. Peptides derived from this region of caveolin also in-
hibit the in vitro kinase activity of puri¢ed MEK-1 and ERK-
2. Our data directly support the hypothesis that caveolar lo-
calization of MEK and ERK can negatively regulate their
signal transduction to the nucleus.
We observed here that co-expression of caveolins with ei-
ther EGF-R, Raf-1, MEK-1, or ERK-2 blocked their ability
to stimulate the transactivation of Elk in vivo. One possibility
is that caveolins may inhibit multiple kinases or ‘nodes’ along
this cascade. Alternatively, caveolins might only inhibit ERK-
2 (the last kinase in the cascade) and still block EGF-R, Raf-
1, and MEK-1 induced transactivation of Elk. We favor the
former possibility, as we have previously shown that caveolin
1 can form a stable hetero-oligomeric complex with EGF-R as
revealed by a series of co-immunoprecipiation studies, and
caveolin-derived peptides will directly inhibit the kinase activ-
ity of the puri¢ed recombinant EGF-R tyrosine kinase in vitro
[38]. In addition, we show here through a series of comple-
mentary in vivo and in vitro domain-mapping studies that
these studies both implicate the same domain of caveolin in
the in vivo and in vitro inhibition of MEK-1 and ERK-2.
How do caveolins negatively regulate these signaling
events? Recent evidence suggests that caveolins function as
kinase inhibitors by recognizing a conserved caveolin-binding
motif that is present within the catalytic domain of many
known kinases. Since the identi¢cation of the caveolin-scaf-
folding domain and caveolin-binding sequence motifs these
observations have been extended to other caveolin-interacting
proteins. Functional caveolin-binding motifs have been de-
duced in both tyrosine and serine/threonine kinases, as well
as in eNOS [28,37^39,57]. In all cases examined, the caveolin
binding motif is located within the enzymatically active cata-
lytic domain of a given signaling molecule. For example, in
the case of tyrosine and serine/threonine kinases, a kinase
domain consists of 11 conserved subdomains (I^XI) [38,39].
The caveolin binding motif is located within conserved kinase
subdomain number IX, suggesting that caveolin could func-
tion as a general kinase inhibitor [38,39]. We suspect that
caveolin inhibits signal transduction from MEK and ERK
by a similar mechanism. This hypothesis is supported by the
observation that the caveolin sca¡olding domain inhibits
EGF-R, PKC, MEK and ERK with similar potency. Thus,
peptide mimetics based on the caveolin-sca¡olding domain
could be used potentially as anti-tumor agents.
Interestingly, we ¢nd that although co-expression of caveo-
lin 2 with EGF-R, Raf-1, MEK-1 or ERK-2 blocks transcrip-
tional activation of Elk in vivo, a peptide derived from the
caveolin-2 sca¡olding domain did not block the activity of
MEK or ERK in vitro. One possible explanation for this
di¡erence between in vivo and in vitro results is that there
may be another region within caveolin 2, other than the scaf-
folding domain, that contains inhibitory activity. In support
of this idea, recent experimental evidence suggests that caveo-
lins may also contain a second inhibitory domain within the
C-terminus [58]. Alternatively, as caveolins 1 and 2 can form a
stable hetero-oligomeric complex in vivo [18], the in vivo ef-
fect of caveolin 2 may be mediated by the caveolin-1/-2 het-
ero-oligomer.
In a recent report, Anderson and colleagues have shown
that the pool of ERK-1 that localizes to caveolae is initially
inactive and can be activated by stimulation with growth fac-
tor ligands, such as PDGF [44]. After such stimulation, acti-
vated ERK-1 translocates to the cytosol, suggesting that
ERK-1 is activated as it leaves the caveolar membrane [44].
These results are consistent with our current ¢ndings that
caveolin-1 expression and direct interaction with caveolin-1
peptides can block signaling from ERK-2 both in vivo and
in vitro, perhaps by sequestering ERK-1/2 and other compo-
nents of the p42/44 MAP kinase cascade in the inactive con-
formation ^ poised for activation by the appropriate cell sur-
face stimulus.
Our results also suggest that a novel reciprocal relationship
may exist between caveolin-1 protein expression and activa-
tion of the p42/44 MAP kinase pathway. We show here that
caveolin 1 can inhibit signal transduction from the p42/44
MAP kinase cascade both in vitro and in vivo. Conversely,
we have previously shown that transformation of NIH 3T3
cells with activated H-Ras (G12V) results in down-regulation
of caveolin-1 protein expression; such down-regulation is re-
versed by treatment of these cells with the MEK inhibitor, PD
98059 [12]. Thus, it appears that constitutive activation of the
p42/44 MAP kinase cascade is su⁄cient to down-regulate cav-
eolin-1 mRNA and protein expression.
Recently, we have identi¢ed a family with an autosomal
dominant form of limb girdle muscular dystrophy. In this
family, a critical region of the caveolin-sca¡olding domain is
deleted within caveolin 3 [59]. Caveolin 3 with this deletion
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acts as a dominant-negative to reduce the total amount of
skeletal muscle caveolin 3 by V95% and results in the classi-
cal symptoms associated with muscular dystrophies [59]. This
¢nding provides the ¢rst genetic evidence that the caveolin-
sca¡olding domain is critical for caveolin functioning in vivo.
Acknowledgements: We thank Drs. G.N. Gill, C. Marshall, R.
Krauss, M. Weber, R. Treisman for generously donating a variety
of cDNA constructions. This work was supported by an NIH FIRST
Award (GM-50443; to M.P.L.), and grants from the G. Harold and
Leila Y. Mathers Charitable Foundation (to M.P.L.) and the Charles
E. Culpeper Foundation (to M.P.L.). J.A.E. was supported by an
NIH Medical Scientist Training Program Grant T32-GM07288. H.J.
is supported by an NIH FIRST Award (HL-53601) and an American
Heart Association Grant-In-Aid (AL-G-960035). A.L. is supported by
an NIH grant (CA73740) and an American Heart Association Scien-
tist Development grant (9630261N). T.O. is supported by an NIH
FIRST Award (MH-56036). T.I. is a fellow of JSPS for Research
Abroad. D.S.K. was supported by an NIH Grant CA-72775 and a
Grant-In-Aid from the American Heart Association.
References
[1] Yamada, E. (1955) J. Biophys. Biochem. Cytol. 1, 445^458.
[2] Severs, N.J. (1988) J. Cell Sci. 90, 341^348.
[3] Fan, J.Y., Carpentier, J.-L., van Obberghen, E., Grunfeld, C.,
Gorden, P. and Orci, L. (1983) J. Cell Sci. 61, 219^230.
[4] Scherer, P.E., Lisanti, M.P., Baldini, G., Sargiacomo, M., Cor-
ley-Mastick, C. and Lodish, H.F. (1994) J. Cell Biol. 127, 1233^
1243.
[5] Scherer, P.E., Okamoto, T., Chun, M., Nishimoto, I., Lodish,
H.F. and Lisanti, M.P. (1996) Proc. Natl. Acad. Sci. USA 93,
131^135.
[6] Simionescu, N. and Simionescu, M. (1983) in: Histology: Cell
and Tissue Biology (Weiss, L., Ed.) pp. 371^433, Elsevier, New
York, NY.
[7] Forbes, M.S., Rennels, M. and Nelson, E. (1979) J. Ultrastruct.
Res. 67, 325^339.
[8] Bretscher, M. and Whytock, S. (1977) J. Ultrastruct. Res. 61,
215^217.
[9] Devine, C.E., Somlyo, A.V. and Somlyo, A.P. (1973) Philos.
Trans. R. Soc. London B 265, 17^23.
[10] Gabella, G. (1973) Philos. Trans. R. Soc. London B 265, 7^16.
[11] Koleske, A.J., Baltimore, D. and Lisanti, M.P. (1995) Proc. Natl.
Acad. Sci. USA 92, 1381^1385.
[12] Engelman, J.A., Wyco¡, C.C., Yasuhara, S., Song, K.S., Oka-
moto, T. and Lisanti, M.P. (1997) J. Biol. Chem. 272, 16374^
16381.
[13] Glenney, J.R. (1989) J. Biol. Chem. 264, 20163^20166.
[14] Glenney, J.R. and Soppet, D. (1992) Proc. Natl. Acad. Sci. USA
89, 10517^10521.
[15] Glenney, J.R. (1992) FEBS Lett. 314, 45^48.
[16] Rothberg, K.G., Heuser, J.E., Donzell, W.C., Ying, Y., Glenney,
J.R. and Anderson, R.G.W. (1992) Cell 68, 673^682.
[17] Kurzchalia, T., Dupree, P., Parton, R.G., Kellner, R., Virta, H.,
Lehnert, M. and Simons, K. (1992) J. Cell Biol. 118, 1003^1014.
[18] Scherer, P.E. et al. (1997) J. Biol. Chem. 272, 29337^29346.
[19] Song, K.S. et al. (1996) J. Biol. Chem. 271, 15160^15165.
[20] Tang, Z.-L. et al. (1996) J. Biol. Chem. 271, 2255^2261.
[21] Way, M. and Parton, R. (1995) FEBS Lett. 376, 108^112.
[22] Sargiacomo, M., Scherer, P.E., Tang, Z.-L., Kubler, E., Song,
K.S., Sanders, M.C. and Lisanti, M.P. (1995) Proc. Natl. Acad.
Sci. USA 92, 9407^9411.
[23] Li, S., Song, K.S. and Lisanti, M.P. (1996) J. Biol. Chem. 271,
568^573.
[24] Murata, M., Peranen, J., Schreiner, R., Weiland, F., Kurzchalia,
T. and Simons, K. (1995) Proc. Natl. Acad. Sci. USA 92, 10339^
10343.
[25] Fra, A.M., Masserini, M., Palestini, P., Sonnino, S. and Simons,
K. (1995) FEBS Lett. 375, 11^14.
[26] Li, S., Okamoto, T., Chun, M., Sargiacomo, M., Casanova, J.E.,
Hansen, S.H., Nishimoto, I. and Lisanti, M.P. (1995) J. Biol.
Chem. 270, 15693^15701.
[27] Song, K.S., Li, S., Okamoto, T., Quilliam, L., Sargiacomo, M.
and Lisanti, M.P. (1996) J. Biol. Chem. 271, 9690^9697.
[28] Li, S., Couet, J. and Lisanti, M.P. (1996) J. Biol. Chem. 271,
29182^29190.
[29] Shaul, P.W., Smart, E.J., Robinson, L.J., German, Z., Yuhanna,
I.S., Ying, Y., Anderson, R.G.W. and Michel, T. (1996) J. Biol.
Chem. 271, 6518^6522.
[30] Garcia-Cardena, G., Oh, P., Liu, J., Schnitzer, J.E. and Sessa,
W.C. (1996) Proc. Natl. Acad. Sci. USA 93, 6448^6453.
[31] Sargiacomo, M., Sudol, M., Tang, Z.-L. and Lisanti, M.P. (1993)
J. Cell Biol. 122, 789^807.
[32] Lisanti, M.P., Scherer, P., Tang, Z.-L. and Sargiacomo, M.
(1994) Trends Cell Biol. 4, 231^235.
[33] Lisanti, M.P., Scherer, P.E., Vidugiriene, J., Tang, Z.-L., Herma-
noski- Vosatka, A., Tu, Y.-H., Cook, R.F. and Sargiacomo, M.
(1994) J. Cell Biol. 126, 111^126.
[34] Anderson, R.G.W. (1993) Proc. Natl. Acad. Sci. USA 90, 10909^
10913.
[35] Fujimoto, T., Nakade, S., Miyawaki, A., Mikoshiba, K. and
Ogawa, K. (1993) J. Cell Biol. 119, 1507^1513.
[36] Fujimoto, T. (1993) J. Cell Biol. 120, 1147^1157.
[37] Couet, J., Li, S., Okamoto, T., Ikezu, T. and Lisanti, M.P. (1997)
J. Biol. Chem. 272, 6525^6533.
[38] Couet, J., Sargiacomo, M. and Lisanti, M.P. (1997) J. Biol.
Chem. 272, 30429^30438.
[39] Oka, N., Yamamoto, M., Schwencke, C., Kawabe, J., Ebina, T.,
Couet, J., Lisanti, M.P. and Ishikawa, Y. (1997) J. Biol. Chem.
272, 33416^33421.
[40] Okamoto, T., Schlegel, A., Scherer, P.E. and Lisanti, M.P. (1998)
J. Biol. Chem. 273, 5419^5422.
[41] Smart, E.J., Ying, Y., Mineo, C. and Anderson, R.G.W. (1995)
Proc. Natl. Acad. Sci. USA 92, 10104^10108.
[42] Mineo, C., James, G.L., Smart, E.J. and Anderson, R.G.W.
(1996) J. Biol. Chem. 271, 11930^11935.
[43] Liu, P., Ying, Y., Ko, Y.-G. and Anderson, R.G.W. (1996)
J. Biol. Chem. 271, 10299^10303.
[44] Liu, P., Ying, Y.S. and Anderson, R.G.W. (1997) Proc. Natl.
Acad. Sci. USA 94, 13666^13670.
[45] Liu, J., Oh, P., Horner, T., Rogers, R.A. and Schnitzer, J.E.
(1997) J. Biol. Chem. 272, 7211^7222.
[46] Pollard, J.W. and Stanners, C.P. (1979) J. Cell Physiol. 98, 571^
585.
[47] Kolch, W., Heidecker, G., Lloyd, P. and Rapp, U.R. (1991)
Nature 349, 426^428.
[48] Wiley, H.S., Herbst, J.J., Walsh, B.J., Lau¡enburger, D.A.,
Rosenfeld, M.G. and Gill, G.N. (1991) J. Biol. Chem. 266,
11083^11094.
[49] Lin, A., Minden, A., Martinetto, H., Claret, F.X., Langer-Carter,
C., Mercurio, F., Johnson, G.L. and Karin, M. (1995) Science
268, 286^290.
[50] Pestell, R.G., Albanese, C., Hollenberg, A. and Jameson, J.L.
(1994) J. Biol. Chem. 269, 31090^31096.
[51] Cowley, S., Patterson, H., Kemp, P. and Marshall, C. (1994) Cell
77, 841^852.
[52] Smith, D. and Johnson, K. (1988) Gene 67, 31^40.
[53] Catling, A.D., Schae¡er, H.J., Reuter, C.W., Reddy, G.R. and
Weber, M.J. (1995) Mol. Cell. Biol. 15, 5214^5225.
[54] Wu, J., Rossomando, A.J., Her, J.H., Del Vecchio, R., Weber,
M.J. and Sturgill, T.W. (1991) Proc. Natl. Acad. Sci. USA A 88,
9508^9512.
[55] Marais, R., Wynne, J. and Treisman, R. (1993) Cell 73, 381^393.
[56] Song, K.S., Tang, Z.-L., Li, S. and Lisanti, M.P. (1997) J. Biol.
Chem. 272, 4398^4403.
[57] Garcia-Cardena, G., Martasek, P., Siler-Masters, B.S., Skidd,
P.M., Couet, J.C., Li, S., Lisanti, M.P. and Sessa, W.C. (1997)
J. Biol. Chem. 272, 25437^25440.
[58] Venema, V.J., Ju, H., Zou, R. and Venema, R.C. (1997) J. Biol.
Chem. 272, 28187^28190.
[59] Minetti, C. et al. (1998) Nat. Genet. 18, 365^368.
FEBS 20236 29-5-98
J.A. Engelman et al./FEBS Letters 428 (1998) 205^211 211
